M&A

From zero to hero: Endocyte’s little deal a year ago spurred a comeback capped by $2.1B Novartis buyout

CAR-T, Collaborations, Research Institutes

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

Restructuring, Workforce

Giant Pfizer looking to shed close to 2,000 jobs as it crafts a ‘simpler’ management structure
More news caret

calendar Protocols

Quick hits from around the biopharma web

Oct 18

Takeda gets Japanese antitrust regulators' blessing for Shire deal; France's Acticor Biotech raises €15.3M for stroke drug

Oct 17

Novotech beefs up Asia-Pacific CRO offering with new buyout as region’s biopharma business booms

Oct 16

Genentech builds new office in Oregon after trimming HQ staff; Researchers laud ketamine as a replacement for opioids

Oct 15

Alnylam shares dip on a decision to scrap accelerated pitch on givosiran; Loxo gets a 'breakthrough' at the FDA

More Protocols caret

person Peer Review

Weekly biopharma careers news report

Oct 12

Perrigo taps ex-tobacco exec as new CEO; Dana Farber T cell investigator Nick Haining joins Merck

Oct 5

Belgian upstart Rewind taps Ian Reynolds as CEO; Robert Foster takes the reins at ContraVir

Oct 1

Ian Read taps his carefully groomed successor Albert Bourla as the next Pfizer CEO. What's his future look like?

Sep 28

Fred Aslan returns to biotech as president of Vividion; Zai Lab scoops Portola's Tao Fu to spearhead US operations

More peer review caret

Dollar Premium

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

bullhorn Bioregnum

The view from John Carroll

Oct 3

Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?

Sep 13

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

Sep 6

Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus

Aug 13

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

More opinion caret

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

Novartis buys Endocyte for $2.1 billion, and an outspoken critic admits he was wrong

STAT a day

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

Novartis a day

Endocyte - And now for something completely different

Open Reading Frame Ohad Hammer a day

Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion

WSJ a day

From zero to hero, Endocyte completes a remarkable transformation

Evaluate.com a day

FDA slaps down Novartis' blockbuster pitch for canakinumab - so what went wrong?

ENDPOINTS NEWS John Carroll a day

Small Molecule Structures: A New World

In the Pipeline Derek Lowe a day

FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic

Federal Trade Commission a day

Toxin or treatment?

Science | AAAS a day

DTC Advertising: The 'Kick Me' Sign On Big Pharma's Backs

Pink Sheet a day

timer Latest

ENDPOINTS NEWS

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

MIT Technology Review

White-people-only DNA tests show how unequal science has become

Science | AAAS

Toxin or treatment?

RAPS

FDA's OPDP Warns MannKind for Facebook Post

Qualtrics

Translating Medical Research

IN

FDA snubs Novartis bid to repurpose inflammation drug for heart...

IN

Fitness trackers' accuracy varies widely for calories burned

Evaluate.com

From zero to hero, Endocyte completes a remarkable transformation

Federal Trade Commission

FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic

Evaluate.com

Bone Therapeutics is rewarded for clinical failure

fire Hot This Week

1

STAT

Harvard and the Brigham call for 31 retractions of cardiac stem cell research - STAT

2

Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency

3

Forbes

Researchers Behind Spinraza Win Breakthrough Prize

4

STAT

Novartis buys Endocyte for $2.1 billion, and an outspoken critic admits he was wrong

5

Novartis

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

6

New York Times

M.I.T. Plans College for Artificial Intelligence, Backed by $1 Billion

7

STAT

Cartoons offer a peek into cancer immunotherapy - and scientists' minds - STAT

8

Open Reading Frame

Endocyte - And now for something completely different

9

WSJ

Pharma Industry Pushes Back Against Required Listing of Drug Prices in TV Ads

10

ENDPOINTS NEWS

Guest column: The real cost of drug development

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back